The Treatment of Advanced Colorectal Cancer

Publication
Article
Special ReportsGastrointestinal Cancers (Issue 1)
Volume 1
Issue 1

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses the treatment of patients with advanced colorectal cancer.

Roberto Bordonaro, MD, chair, medical oncology, Garibaldi Hospital, Catania, Italy, discusses the treatment of patients with advanced colorectal cancer (CRC).

Read more about the treatment of CRC andthe need for fullRASmutational analyses > >

Articles in this issue
The Identification of Molecular Subtypes of Gastric Cancer
The Identification of Molecular Subtypes of Gastric Cancer
Ramucirumab Combo Increases Survival in Gastric Cancer
Ramucirumab Combo Increases Survival in Gastric Cancer
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Data
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Data
New Standard of Neoadjuvant Care for Rectal Cancer Established
New Standard of Neoadjuvant Care for Rectal Cancer Established
Reducing the Risk of Relapse in Patients With Pancreatic Cancer
Reducing the Risk of Relapse in Patients With Pancreatic Cancer
Vismodegib Demonstrates Activity in Advanced Pancreatic Cancer
Vismodegib Demonstrates Activity in Advanced Pancreatic Cancer
The Treatment of Advanced Colorectal Cancer
The Treatment of Advanced Colorectal Cancer
Studies Emphasize Need for Full <em>RAS</em> Mutational Analyses in the Management of mCRC
Studies Emphasize Need for Full <em>RAS</em> Mutational Analyses in the Management of mCRC
TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCC
TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCC
Recent Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Related Content
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC

Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC

Targeted Oncology Staff
December 21st 2024
Article

During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

Luspatercept: A Challenge to Erythropoietin and Its Role in Boosting QOL in MDS

Luspatercept: A Challenge to Erythropoietin and Its Role in Boosting QOL in MDS

Targeted Oncology Staff
December 20th 2024
Article

Solly Chedid, MD, discussed luspatercept and its role in boosting quality of life for patients with myelodysplastic syndrome.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

The Promise of Metabolomics to Transform Breast Cancer Screening

The Promise of Metabolomics to Transform Breast Cancer Screening

Morgan Bayer
December 19th 2024
Article

One new frontier of cancer detection is emerging: metabolomics.

Read More

Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL

Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL

Targeted Oncology Staff
December 18th 2024
Article

During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.

Read More